https://wikimd.org/index.php?action=history&feed=atom&title=SaroglitazarSaroglitazar - Revision history2026-05-02T04:36:11ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Saroglitazar&diff=6335175&oldid=prevPrab: CSV import2025-02-20T01:35:52Z<p>CSV import</p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 01:35, 20 February 2025</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l25">Line 25:</td>
<td colspan="2" class="diff-lineno">Line 25:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{stub}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{stub}}</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><gallery></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">File:Saroglitazar skeletal.svg|Saroglitazar</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></gallery></ins></div></td></tr>
</table>Prabhttps://wikimd.org/index.php?title=Saroglitazar&diff=5167854&oldid=prevPrab: CSV import2024-02-19T23:26:07Z<p>CSV import</p>
<p><b>New page</b></p><div>'''Saroglitazar''' is a medication primarily used for the treatment of [[diabetic dyslipidemia]] and [[hypertriglyceridemia]]. It is a dual [[PPAR agonist]], exerting its effects on both PPAR alpha and PPAR gamma receptors. Saroglitazar was developed by [[Zydus Cadila]], an Indian pharmaceutical company, and received approval from the [[Drug Controller General of India]] (DCGI) in June 2013.<br />
<br />
==Etymology==<br />
The name "Saroglitazar" is derived from the words "Saro" and "glitazar". "Saro" is a prefix used in pharmaceutical naming to denote a connection to the [[Saroglitazar family]], while "glitazar" is a suffix used for drugs that act as [[PPAR agonists]].<br />
<br />
==Pharmacology==<br />
Saroglitazar is a dual PPAR agonist, meaning it activates both the PPAR alpha and PPAR gamma receptors. These receptors play a crucial role in the regulation of [[lipid metabolism]] and [[glucose homeostasis]], respectively. By activating these receptors, Saroglitazar helps to reduce levels of [[triglycerides]] and increase levels of [[HDL cholesterol]], while also improving [[insulin sensitivity]].<br />
<br />
==Clinical Use==<br />
Saroglitazar is primarily used for the treatment of diabetic dyslipidemia and hypertriglyceridemia. Diabetic dyslipidemia is a condition characterized by high levels of triglycerides and low levels of HDL cholesterol in patients with [[diabetes]]. Hypertriglyceridemia, on the other hand, is a condition characterized by excessively high levels of triglycerides in the blood.<br />
<br />
==Side Effects==<br />
Like all medications, Saroglitazar can cause side effects. The most common side effects include [[nausea]], [[headache]], and [[upper respiratory tract infection]]. Less common side effects can include [[hypoglycemia]], [[edema]], and [[anemia]].<br />
<br />
==Related Terms==<br />
* [[PPAR agonist]]<br />
* [[Diabetic dyslipidemia]]<br />
* [[Hypertriglyceridemia]]<br />
* [[Zydus Cadila]]<br />
* [[Drug Controller General of India]]<br />
<br />
[[Category:Medicine]]<br />
[[Category:Pharmacology]]<br />
[[Category:Diabetes]]<br />
<br />
{{stub}}</div>Prab